Johns Hopkins International Vaccine Access Center Executive Director William Moss discusses ways to safely accelerate the coronavirus vaccine development process, challenges in delivering a vaccine to patients, and the differences between antibody treatments and a vaccine.

While 70% of those surveyed expressed willingness to get vaccinated, about half preferred to wait to make sure the shots are safe and 27% said they wouldn’t want to get vaccinated.

The total number of contact tracers reported in all U.S. states and territories was 53,116, falling far short of the more than 100,000 public health experts have been calling for since the pandemic began.

This week, two high-profile, late-stage clinical trials — Johnson & Johnson’s test of a coronavirus vaccine and Eli Lilly’s study of a COVID-19 drug — were put on pause because of possible safety concerns.

A pair of new studies assert that the U.S. response to the COVID-19 pandemic has been a disaster, causing more deaths than thought and prolonging Americans' suffering more than any other country.

Health officials, including experts from the Johns Hopkins Bloomberg School of Public Health, are coming around to the conclusion that they do more harm than good, except in limited circumstances.

The coronavirus pandemic may have caused tens of thousands of more deaths than previously thought, according to a report published Monday in the peer-reviewed journal JAMA.

Johns Hopkins Bloomberg School of Public Health Vice Dean Joshua Sharfstein explains the flawed thinking behind herd immunity. 

Dr. Joshua M. Sharfstein, professor at the Johns Hopkins Bloomberg School of Public Health, coauthors a piece on the importance of isolation following a COVID-19 diagnosis.

Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Bloomberg School of Public Health, discusses the current number of COVID-19 cases in the U.S.

Death rates from the novel coronavirus are lower in hot spots around the world, even as new infections accelerate in what may be the pandemic’s next wave.

People on remdesivir recovered in 10 days, on average, compared with 15 days for those only receiving supportive care like oxygen and IV fluids, according to the results published Oct. 8 in the New England Journal of Medicine.